person · Reporting owner
Pai Panandiker Kaya Kamlesh
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Chief Commercial Officer | December 10, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LB PHARMACEUTICALS INC
Report date December 10, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.36 · Expires 2035-12-09 | Direct | 195,000 |
Reported balance
After 2025-12-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-10 · Grant · Acquired 195,000 · Balance 195,000 F1: One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2025 Filed Dec 11, 2025 21:15 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0002095250-25-000006 · form4-12112025_041206.xml · derivative · entry 1 Pai Panandiker Kaya Kamlesh · CIK 0002095250 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2035-12-09 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.